March 16, 2016 6:36am
Like “our” universe, toss a marker into square number two and repeat the pattern.
Jump through one or two spaces to retrieve share price appreciation?
For your pre-open briefing, subscribe … http://www.regmedinvestors.com/create-account
I say today what others won't, so you can do what others can't; whether information or intelligence is good, bad or somewhere in between – it defines the who, when, where, which and what of it …
Dow futures are UP +0.13% and NASDAQ futures are UP +0.2%
U.S. stock futures inch higher, with market in holding pattern ahead of Fed as futures point to a slightly higher open as investors brace for a key Federal Reserve policy statement due in the afternoon
European equities edged higher as markets await the latest interest rate decision from the U.S. Federal Reserve's monetary policy committee.
Asia markets closed mixed Wednesday, following a weaker finish on Wall Street overnight as traders await the U.S. Federal Reserve decision due later.
Data docket: Ahead of the opening bell, they are expected to digest reports on consumer prices, housing starts and industrial production. Federal Reserve policy makers are expected to wrap up a two-day meeting and make an announcement at 2 p.m. ET, with the CME Group’s FedWatch tool giving a 0% chance of an interest-rate hike. Fed chief Janet Yellen is slated to hold a news conference at 2:30 p.m. ET.
The stem, cell and gene therapy RegMed sector closed NEGATIVE on Tuesday, POSITIVE on Monday and Friday, NEGATIVE on Thursday and POSITIVE on last Wednesday.
Last five (5) days (of 43 covered companies):
· Tuesday closed NEGATIVE with 32 decliners, 9 advancers and 2 flats;
· Monday closed POSITIVE with 18 decliners, 23 advancers and 2 flats;
· Friday closed POSITIVE with 7 decliners, 34 advancers and 2 flats;
· Thursday closed NEGATIVE with 27 decliners, 15 advancers and 1 flat;
· Last, Wednesday closed POSITIVE with 19 decliners, 23 advancers and 1 flat;
The stem, cell and gene therapy regenerative medicine (SCGT&RM) sector opened down, stayed negative at the mid-day and closed to the downside with 32 in the red column covered of 43 companies on Tuesday!
- Keeping Monday’s end-of-day hat on … “The stem, cell and gene therapy regenerative medicine sector keeps seeking a bottom– there are just too many under-currents.”
Financial results/earnings news is not good, but it’s also not all bad– some cash positions are solid.
- Reiterating, “…news is slow and financial results/earnings continue with many afraid of reporting consequences of those who haven’t reported Q4/15, many could be caught with pre call jitters and post reporting depreciation.
That does not mean that you can't find some decent short to near-term entry points among our 43 company coverage … to trade!
- Then again, the second full week of March has never been a safe time to rule out anything.
You’ve made it to the office, turned on the monitor having just gotten your coffee and it hits you - what could be Wednesday’s trades?
- Applied Genetic Technologies (AGTC) closed DOWN -$1.01 to $13.42. AGTC bolts, fades and bolts again after Monday’s $14.43, Friday’s $14.20, Thursday’s $13.92, last Wednesday’s $14.28, Tuesday’s $13.99 and the previous Monday’s $14.76. The closing numbers speak of being oversold – BUY;
- Caladrius Biosciences (CLBS) closed DOWN -$0.09 to $0.86. The net loss attributable to stockholders for Q4/15 was $33.2 M or $0.59 per share, compared to $11.6 M or $0.32 per share for Q4/14. The real issue is the net loss to stockholders for 2015 was $80.9 M or $1.67 per share based on 48.5 M shares outstanding, compared to $54.9 M or $1.68 per share based on 32.8 M shares outstanding for 2014. After three major “faults” of their platforms, a dismissed CFO and a struggling CEO even with a divisional unit PCT selling 19.9% being sold to Hitachi Chemical – this company is in trouble. NASDAQ will also be knocking re listing issues; CEO Mazzo should have sold the company and reaped a change of control clause of his contract – a pattern he has successfully enacted multiple times in the past. The after-market indication is -$0.06 – short-term BUY to SELL;
- Intrexon (XON) closed DOWN -$3.23 to $34.19. XON announced <Saturday> the FDA-CVM published preliminary findings-of-no-significant impact (FONSI) < A FONSI is issued when environmental analysis and interagency review during the EA process find a project to have no significant impacts on the quality of the environment.> on its self-limiting OX513A Aedes aegypti mosquito. The US FDA's Center for Veterinary Medicine today released in the Federal Register this preliminary FONSI on Oxitec's (a subsidiary of XON) self-limiting OX513A Aedes aegypti mosquito for an investigational trial in the Florida Keys. The finding agrees with the draft environmental assessment submitted by Oxitec that concludes a field trial of XON's genetically engineered OX513A mosquitoes in Key Haven, Florida, will not result in a significant impact on the environment. The after-market indication is +$0.12 – BUY;
- Juno Therapeutics (JUNO) closed DOWN -$3.38 to $36.79 after Monday’s +$0.17 after Friday’s +$0.91. The after-market indication is -$0.41. JUNO is constantly fighting the battle of oversold versus overbought by traders – short-term SELL to BUY;
- Kite Pharma (KITE) closed DOWN -$3.98 to $44.91. Another hopscotch game of jumping forward and back again. The after-market indication is -$0.18. It’s a trading market, not an investing scenario – SELL;
- Osiris (OSIR) closed DOWN -$0.23 to $5.13 after Monday’s $5.36 which was down -$0.05. On March 15, 2016, OSIR notified The NASDAQ of the Company's anticipated failure to timely file its Annual Report on Form 10-K for the year ended 12/31/15 in compliance with NASDAQ's Rule 5250(c)(1), which requires that listed companies file their required periodic financial reports with the SEC on a timely basis. The after-market indication is -$0.38 – SELL;
- Vericel (VCEL) closed UP +$0.41 to $4.54 after Monday’s -$0.20 after Friday’s +$0.38 following Thursday’s upside of +$1.83. The after-market indication is -$0.04. Another, I believe investors and traders are chasing an upside – it might work for a day or two but, on the whole, it doesn’t work – Maintaining SELL;
- Spark Therapeutics (ONCE) closed DOWN -$1.69 after Monday’s +$0.38 after Friday’s +$1.94. The run-up scares me as traders are always ready to profiteer. The after-market indication is -$0.11 – Maintaining SELL;
Opinions expressed are those of the author and are subject to change, and are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
